Non-Hormonal Treatments for Menopause: SSRIs, Gabapentin, and Beyond

Key Takeaways

• Hormone therapy remains most effective for vasomotor symptoms, but non-hormonal options now offer real relief for women who cannot or prefer not to use HRT
• Fezolinetant, an NK3 antagonist, shows the strongest evidence among new medications, reducing hot flashes by up to 70% in clinical trials
• Low-dose paroxetine (Brisdelle) is FDA-approved and reduces hot flashes by roughly 60%, with effects appearing within weeks
• CBT and clinical hypnosis produce measurable reductions in hot flash impact comparable to some medications, without side effects
• Supplements like black cohosh have weak evidence; acupuncture shows mixed results in large trials
• Lifestyle changes (sleep, stress, cooling strategies) form the foundation; evidence-based medications and therapy amplify these effects

The Real Situation with Non-Hormonal Treatment

Hormone therapy has been the gold standard for menopause symptoms for decades. It works well. It's effective. But it's not the only path, and for some women it isn't an option at all.

Maybe you had breast cancer. Maybe you have a history of blood clots. Maybe hormones make you feel strange, or you prefer not to take them. Or maybe you want to see what non-hormonal options can do before moving to HRT.

The landscape has shifted in the past few years. We now have better data on what actually works without hormones. Not everything. Some popular supplements remain unproven. Some older treatments are less effective than we once hoped. But there are real options, backed by rigorous research, that can make a genuine difference in how menopause feels.

This guide walks through what the evidence actually shows about non-hormonal treatments, separating the science from the marketing and the hype from the real gains.

Why Non-Hormonal Options Matter

Not every woman can take hormone therapy. Roughly 25-40% of perimenopausal and menopausal women have contraindications to estrogen or progestin, or they simply prefer non-hormonal approaches.

Absolute contraindications to HRT include:

• Active estrogen-dependent breast cancer
• Recent or current venous thromboembolism (blood clots)
• Uncontrolled high blood pressure (in some cases)
• Active liver disease

Many women choose non-hormonal options because:

• They want to minimize medication exposure
• They have mild to moderate symptoms that don't require the strongest intervention
• They want to try behavioral or mind-body approaches first
• They're concerned about long-term use of hormones
• They want options for partial symptom relief alongside other strategies

The evidence shows that non-hormonal treatments often work better than women expect, especially when combined. A woman using gabapentin at night, practicing paced breathing during the day, and working with a therapist may find that her hot flashes drop from eight per day to two or three and feel far less disruptive.

That's real relief. That matters.

Fezolinetant (Veozah): The New NK3 Antagonist

In September 2023, the FDA approved fezolinetant, marketed as Veozah, marking the first major shift in pharmacologic options for non-hormonal menopause treatment in over a decade.

How it works: Vasomotor symptoms originate in a specific part of the brain called the hypothalamus, where a cluster of neurons called the KNDy neurons regulate body temperature. These neurons are modulated by neurokinin-3 (NK3) receptors. Fezolinetant blocks NK3 receptors, essentially quieting the system that triggers hot flashes and night sweats.

Clinical evidence: The SKYLIGHT 1 and SKYLIGHT 2 trials, published in 2023, tested fezolinetant in over 4,000 women with moderate-to-severe vasomotor symptoms. Results showed:

• Women taking fezolinetant 45 mg daily experienced roughly 70% reduction in hot flash frequency at 12 weeks
• Women on placebo experienced about 20% reduction (the placebo effect in hot flash trials is notable)
• The net benefit was approximately 50 percentage points better than placebo
• Benefits appeared by week 4 and continued through 12 weeks of treatment
• An extension phase showed sustained benefit over 52 weeks

Side effects: The most common side effects were mild and similar to placebo: nausea (6-8% of users), headache, and dizziness. A concern raised during development was potential liver toxicity, but actual clinical trials showed very low rates of liver enzyme elevation (fewer than 1% of participants). Liver monitoring (baseline and periodically during treatment) is recommended but not intensive.

Cost and access: Veozah is expensive. Without insurance, the monthly cost runs approximately $300-400. Most insurance plans require prior authorization, and some may not cover it, particularly if SSRIs or other cheaper options haven't been tried first.

Practical considerations: Fezolinetant is once-daily dosing and doesn't interact significantly with other medications. It's truly non-hormonal, making it an option even for women with breast cancer (though use in this population requires discussing with an oncologist). It typically becomes effective within 4 weeks, similar to SSRIs.

For women who fail or can't tolerate other non-hormonal options, fezolinetant represents a genuine advance.

Elinzanetant: The Pipeline Candidate

Another NK3 antagonist, elinzanetant, is in late-stage development. It's a dual NK1/NK3 receptor antagonist, meaning it blocks two temperature-regulating pathways instead of one.

Early data from 2024 studies suggests elinzanetant may work comparably to fezolinetant, perhaps with a slightly different side effect profile. As of early 2025, it remains in the approval pipeline but hasn't yet received FDA authorization.

If approved, elinzanetant may offer an alternative for women who don't tolerate fezolinetant or want options. For now, fezolinetant is the only NK3 antagonist available.

SSRIs and SNRIs: The Antidepressants

Before fezolinetant, SSRIs and SNRIs (serotonin-based antidepressants) were the most commonly prescribed non-hormonal medications for menopause symptoms. They remain excellent options, particularly for women who also experience low mood or anxiety.

How they work: The exact mechanism for why SSRIs and SNRIs reduce hot flashes remains incompletely understood. They don't work through serotonin alone; rather, they likely influence multiple neurotransmitter systems involved in temperature regulation.

Approved option: Low-dose paroxetine (Brisdelle): In 2013, the FDA approved paroxetine at a specially formulated low dose (7.5 mg) specifically for menopausal hot flashes. This is the only SSRI with an FDA-labeled indication for vasomotor symptoms.

Clinical trials in roughly 1,200 women showed:

• Hot flash reduction of approximately 60% compared to roughly 20% with placebo
• Benefits appear within 1-2 weeks of starting (faster than other SSRIs)
• Side effects are minimal at this low dose; nausea was the most common but subsided within a few days for most women

Other SSRIs and SNRIs: Many women benefit from other SSRIs at standard doses, though less data supports specific recommendations.

• Escitalopram: Meta-analyses suggest escitalopram may be the most effective SSRI for hot flashes, with some studies showing 50%+ reduction in hot flash severity
• Venlafaxine: An SNRI showing roughly 40-60% reduction in hot flashes; some studies show benefit within one week
• Desvenlafaxine: Similar effectiveness to venlafaxine; some women tolerate it better
• Sertraline and other SSRIs: Likely effective but less-studied than the above

Side effects: Common mild effects include nausea (improves within days), headache, dry mouth, and sexual dysfunction. Most improve with continued treatment.

Important warning: Women on tamoxifen should avoid paroxetine and fluoxetine, as they reduce tamoxifen effectiveness. Sertraline, citalopram, and venlafaxine are better alternatives.

Timeline: Unlike hormone therapy, which can take 2-3 months to reach full effectiveness, SSRIs often show benefit within 2-4 weeks.

Gabapentin and Pregabalin: The Nerve Medications

Originally developed for nerve pain, gabapentin and pregabalin (Lyrica) have shown consistent benefit for hot flashes and especially for night sweats.

Effectiveness: Large trials show gabapentin at 900 mg per day reduces hot flash frequency by roughly 35-50% compared to placebo, with some higher-dose studies reporting up to 60-80% improvement. The benefits appear within 2-4 weeks.

Pregabalin has fewer studies but shows similar effectiveness. Women whose main complaint is night sweats causing sleep disruption often report the best results with these medications.

Why it works for night sweats: Gabapentin works partly by reducing hot flashes directly, but also by improving sleep quality and reducing anxiety, both of which contribute to night sweat severity.

Side effects: The sedation question The most common side effect is drowsiness or dizziness. Here's the practical point: for some women, this is a bug; for others, it's a feature. A woman kept awake by night sweats may find that the sedating effect of gabapentin helps her sleep despite the flashes.

Dizziness and drowsiness typically peak in the first week then fade significantly by week 3-4. Most women report they adapt to the medication.

Gabapentin also has no drug interactions, no hormonal effects, and is inexpensive.

Dosing: Standard dosing is 300 mg three times daily (900 mg total), though some women tolerate or prefer 1,800 mg daily divided into three doses.

Oxybutynin and Clonidine: The Older Options

These medications predate SSRIs and are less commonly prescribed for menopause now, but they have evidence supporting their use.

Oxybutynin: An anticholinergic medication originally used for urinary incontinence. Studies show modest effectiveness for hot flashes, roughly comparable to SSRIs. The NAMS 2023 position statement classifies it as recommended with good evidence.

Main drawback: dry mouth is common and can be bothersome. Oxybutynin is inexpensive and well-established, making it an option if other treatments don't work or aren't tolerated.

Clonidine: A blood pressure medication that has mild effectiveness for hot flashes (roughly 20-40% reduction). It's rarely prescribed anymore as first-line therapy given better alternatives exist. Dry mouth and dizziness are common.

Both medications play a role in the non-hormonal toolkit but are usually reserved for women who don't tolerate or don't respond to SSRIs or gabapentin.

Cognitive Behavioral Therapy for Menopausal Symptoms (CBT-Meno)

CBT is a structured form of psychotherapy focused on changing how thoughts and behaviors influence physical symptoms. When applied to menopause, it's brief, evidence-based, and surprisingly effective.

The protocol: The most-studied version, developed by researcher Myra Hunter at King's College London, is called CBT-Meno or MENOS. It consists of 4-6 sessions over a few weeks, each about 45 minutes.

Sessions focus on:

• Understanding the thought patterns and behaviors that amplify hot flashes
• Identifying and modifying unhelpful beliefs (for example: "This hot flash means something is wrong with me")
• Learning and practicing coping strategies (breathing, self-talk, problem-solving)
• Addressing sleep problems and stress that worsen symptoms
• Behavioral activation and lifestyle changes

What the evidence shows: Multiple randomized controlled trials show CBT reduces the impact of vasomotor symptoms by roughly 50% compared to a waiting list control. This isn't about hot flashes disappearing; it's about them feeling less distressing and disruptive.

Studies have included well women, breast cancer survivors (where hormones aren't an option), and women with treatment-resistant hot flashes. Results hold across these groups.

Importantly, benefits persist long after treatment ends. A woman who completes CBT-Meno may continue experiencing improvements for months.

Delivery formats: CBT has been delivered effectively in:

• Individual in-person sessions
• Group settings
• Self-help books with or without coaching
• Online platforms with or without therapist contact

All formats show benefit, though in-person or guided formats may produce larger gains.

Access and cost: Finding a therapist trained specifically in CBT-Meno can be challenging, as it's not yet mainstream. Many therapists trained in standard CBT can adapt protocols for menopause. Cost varies widely depending on insurance and location; some plans cover therapy as preventive care.

Limitations: CBT requires active engagement from the woman. It's not a passive treatment. It also works better for women with some insight into their symptom patterns and willingness to examine their thoughts and behaviors.

Clinical Hypnosis: Underutilized and Evidence-Based

Of all non-hormonal treatments, clinical hypnosis is among the most misunderstood. It's not stage hypnosis. It's not mind control. It's a therapeutic technique using focused attention and suggestion to bypass the analytical mind and access deeper pattern-changing processes.

The research: Dr. Gary Elkins at Baylor University conducted a landmark randomized controlled trial with 187 postmenopausal women with an average of 7+ hot flashes daily. Results showed:

• Clinical hypnosis group experienced a 74% reduction in hot flash frequency (from roughly 79 flashes per day to 18)
• Control group experienced a 17% reduction (placebo effect)
• The net gain from hypnosis was remarkable: roughly 57 percentage points better than control
• Improvements in sleep quality and quality of life were also significant
• Results held at 26-week follow-up

A follow-up study from Elkins' group showed that clinical hypnosis outperformed cognitive behavioral therapy in reducing hot flash frequency in direct comparison, though both are effective.

How it works: During a hypnosis session, a trained clinician guides the woman into a state of focused attention, often using progressive relaxation and guided imagery. Suggestions target the perception and response to hot flashes. For example: cooling imagery, reframing hot sensations as neutral rather than distressing, or mental anchors for managing symptoms when they occur.

Contrary to common belief, women remain fully conscious. They hear everything. They can reject suggestions that don't feel right.

Hypnotizability and effectiveness: While hypnotizability predicts benefit, it's not absolute. Even low-hypnotizable women showed improvement.

Access and limitations: The main barrier is finding a trained clinician. Clinical hypnosis for menopause isn't widely available. Board-certified hypnotherapists or psychologists trained in clinical hypnosis are concentrated in academic medical centers and major cities.

Cost is often out-of-pocket. Some insurance plans cover hypnotherapy when delivered by licensed mental health professionals, but coverage is inconsistent.

Bottom line: For women who can access it, clinical hypnosis offers substantial, sustained benefit without medication. It may be particularly valuable for women with anxiety around hot flashes or those who had positive responses to therapeutic interventions.

Mind-Body: Mindfulness, Paced Breathing, and Yoga

The evidence for purely behavioral non-pharmacologic approaches is more limited but worth understanding clearly.

Paced breathing: Multiple randomized trials tested paced breathing (typically slow, deep breathing at 5-6 breaths per minute) as a standalone treatment for hot flashes. The evidence is not promising. Large trials found no significant reduction in hot flash frequency or severity from paced breathing alone.

However, paced breathing appears in many non-hormonal treatment recommendations, often supported by small studies or mechanistic rationale. The reality: it's unlikely to meaningfully reduce hot flashes on its own, though it may help with stress and anxiety accompanying symptoms.

Yoga and tai chi: The picture is mixed. Some yoga studies report improvements in vasomotor and menopausal symptoms; others show yoga is no better than basic exercise. Most studies suffer from design limitations (small sample sizes, inadequate control groups, high dropout rates).

Where the evidence is clearer: yoga improves general quality of life, stress, and sleep in menopausal women, even if hot flash reduction is modest or inconsistent.

Mindfulness and meditation: Mindfulness-based interventions show promise for improving quality of life and psychological symptoms in menopausal women. Evidence for reducing hot flash frequency or severity is less clear.

What NAMS concluded: The 2023 North American Menopause Society position statement recommends CBT and clinical hypnosis as mind-body approaches with good evidence. Yoga and other relaxation techniques are considered supportive for overall wellbeing but not specifically for vasomotor symptom reduction.

The practical takeaway: mind-body approaches are most valuable as part of a multi-faceted approach rather than as standalone treatments. A woman doing yoga, practicing mindfulness, and taking an SSRI may do better than someone using any single approach alone.

Supplements: An Honest Evaluation

The supplement industry markets aggressively to menopausal women. The evidence, unfortunately, doesn't match the marketing. Here's what rigorous research actually shows.

Black cohosh (Cimicifuga): Among the most-studied supplements, with 16 randomized controlled trials included in the most recent Cochrane systematic review. The conclusion: insufficient evidence to support black cohosh use for menopausal vasomotor symptoms.

When compared directly to placebo, black cohosh showed no significant benefit in reducing hot flash frequency or severity in most trials. When compared to estrogen, estrogen was substantially more effective.

Black cohosh is safe (liver toxicity concerns were raised but aren't supported by evidence), but it simply doesn't work reliably for hot flashes. Some women report subjective benefit, possibly reflecting individual variation or placebo response.

Soy isoflavones: Soy contains plant-derived estrogens called isoflavones. The logic: they might mimic estrogen effects without the risks. The evidence is modest.

Meta-analyses show small reductions in hot flash frequency (roughly 10-20% beyond placebo) and minimal to no effect on hot flash severity. If soy helps, the effect is weak.

Also important: soy's interaction with tamoxifen is controversial. Most experts consider soy safe for breast cancer survivors, but some oncologists recommend limiting high-dose isoflavone supplements while on tamoxifen.

Red clover: Contains isoflavones similar to soy. Evidence is similarly weak. Cochrane reviews and meta-analyses find insufficient evidence of benefit for vasomotor symptoms.

Evening primrose oil: Proposed mechanism: omega-6 fatty acids might reduce inflammation and influence hot flashes. The evidence: minimal. Large trials show no benefit over placebo. It appears in some supplement protocols but lacks substantive research support.

Maca: A Peruvian plant supplement promoted for hormonal balance and sexual function. Trials for menopausal vasomotor symptoms are few and of poor quality. No reliable evidence supports its use for hot flashes.

Vitamin E: Large, well-designed trial (part of the Women's Health Initiative) found that 400 IU daily vitamin E produced no significant reduction in hot flash frequency or severity compared to placebo.

Summary on supplements: The honest assessment is that most botanical supplements marketed for menopause lack meaningful evidence. Black cohosh, soy, and red clover have been studied most rigorously and show weak to no benefit. Even high-quality supplements don't compensate for lack of efficacy.

That doesn't mean supplements are harmful or that individual women can't benefit from them. It means the population-level evidence for vasomotor symptom reduction is not strong. If a woman has tried them and feels they help, continuing is reasonable. But they shouldn't be relied upon as primary treatment for moderate-to-severe symptoms.

Acupuncture: Mixed Evidence in Large Trials

Acupuncture enjoys popularity among women seeking non-pharmaceutical approaches. The mechanistic story is plausible: acupuncture influences neurotransmitter systems involved in temperature regulation.

What large trials show: The most rigorous evidence comes from sham-controlled randomized trials (where some women receive real acupuncture and others receive acupuncture at non-therapeutic points, designed to look identical). In these trials, acupuncture's benefit over sham treatment is minimal.

Some smaller trials report benefit, but quality issues (lack of proper blinding, small sample sizes, risk of bias) limit confidence in those findings.

Cochrane assessment: The Cochrane Database found insufficient evidence to recommend acupuncture for menopausal vasomotor symptoms based on available trials.

Why the appeal? Acupuncture is associated with relaxation, attention from a practitioner, and time devoted to wellness. These contextual factors likely account for much of the benefit women report. That's not nothing, but it also isn't the same as a specific physiologic effect on hot flashes.

Practical considerations: Acupuncture is safe in trained hands. If a woman wants to try it, understanding that benefit is likely modest and possibly non-specific (similar to benefit from any attentive therapeutic interaction) sets realistic expectations. It may help with stress and wellbeing even if hot flash reduction is limited.

Stellate Ganglion Block: Emerging Option with Limited Evidence

SGB involves injecting local anesthetic near neck nerves regulating temperature. Small pilot studies reported hot flash reduction, but large rigorous trials are lacking. Current evidence is insufficient to recommend for routine use. The procedure carries real risks (nerve damage, pneumothorax, vascular injury) and costs $500-2000 per injection (usually not covered). SGB remains experimental at this time.

Lifestyle Foundations: The Unglamorous but Essential Base

All medications and therapies work better when lifestyle factors are optimized. These aren't substitutes for treatment but multipliers of treatment efficacy.

Sleep and sleep environment: Poor sleep amplifies both hot flashes and the distress they cause. Optimizing sleep:

• Keep bedroom cool (around 65-68 degrees Fahrenheit)
• Use breathable, moisture-wicking bedding
• Avoid alcohol in the evening (it can trigger night sweats)
• Establish regular sleep and wake times
• Consider silk or bamboo pillowcases and sheets

Good sleep hygiene enhances any medical treatment.

Stress and emotional wellbeing: Stress amplifies hot flashes physiologically. Women who practice stress management, whether through meditation, therapy, exercise, or simply taking breaks, typically experience less bothersome symptoms.

This is mechanistic, not psychological. The stress response directly influences the hypothalamic systems that generate hot flashes.

Weight and metabolic health: Overweight and obesity are associated with more frequent and bothersome vasomotor symptoms. Modest weight loss (even 5-10% of body weight) is associated with symptom improvement.

This isn't about appearance. Adipose tissue produces estrogen and inflammatory molecules that can amplify hot flashes. The mechanism is real.

Smoking cessation: Smoking is associated with more severe vasomotor symptoms and earlier menopause onset. Quitting improves symptoms.

Heat management: Simple behavioral strategies matter. Women can:

• Dress in layers that can be removed quickly
• Keep a water bottle at hand
• Identify and avoid personal triggers (spicy food, hot beverages, warm environments)
• Practice paced breathing when a flash starts (even if paced breathing alone doesn't prevent them, it can reduce panic and severity)

Alcohol reduction: Alcohol is a hot flash trigger for many women. Reducing intake, particularly in the evening, can meaningfully improve symptoms.

Exercise and activity: Regular aerobic and strength training improve vasomotor symptoms, sleep, mood, and cardiovascular health. The effect is modest but real. Most recommendations suggest 150 minutes of moderate activity weekly.

Vaginal and Genitourinary Symptom-Specific Options

Many menopausal women experience vaginal dryness, irritation, and pain with intercourse (genitourinary syndrome of menopause). These warrant specific non-hormonal (and hormonal) treatments beyond systemic vasomotor symptom management.

Vaginal moisturizers: Over-the-counter products containing hyaluronic acid (Hyalo Gyn, Hypertears, others) or glycerin provide consistent moisture. Use 2-3 times weekly.

These work for mild dryness but don't address painful intercourse caused by atrophy.

Vaginal lubricants: Used during intercourse for immediate symptom relief. Many options available (water-based, silicone-based, natural oils). Silicone-based lubricants last longer but may damage silicone toys/barriers.

Ospemifene (Osphena): An oral selective estrogen receptor modulator (SERM) FDA-approved for moderate-to-severe pain with intercourse due to menopause-related atrophy. It's non-hormonal in the traditional sense but acts like estrogen in vaginal tissue.

Clinical trials show improvement in vaginal dryness and pain with intercourse. Benefits appear by 12 weeks. Side effects are similar to hormone therapy: hot flashes may worsen, vaginal bleeding possible (since ospemifene has systemic effects). Not for women with active breast cancer.

Vaginal DHEA (Prasterone, Intrarosa): A precursor to estrogen and testosterone, applied nightly as an insert. Shows benefit for vaginal dryness, painful intercourse, and sexual function.

Some absorption occurs systemically, though blood levels of DHEA and hormones remain low. Vaginal bleeding and breast tenderness can occur. Cost is high.

Pelvic floor physical therapy: Women with muscle tension, trigger points, or weakness can benefit from PT focused on pelvic floor muscles. A trained physical therapist can address pain with intercourse and improve sexual function.

This is underutilized but evidence-supported. Insurance often covers it.

What the Research Says: A Hierarchy of Evidence

Not all evidence is created equal. Understanding the strength of evidence for different treatments helps set realistic expectations.

Strongest evidence (Level 1, multiple large RCTs):

• Hormone therapy (HRT) remains the gold standard, most effective for vasomotor symptoms
• Fezolinetant
• Paroxetine and other SSRIs/SNRIs
• Gabapentin
• CBT and clinical hypnosis

These treatments have substantial, replicated evidence. They work reliably for many women.

Good evidence (Level 2, smaller or fewer RCTs):

• Oxybutynin
• Venlafaxine specifically (good evidence for this particular SNRI)
• Ospemifene (for genitourinary symptoms)

These are evidence-based but either have fewer studies or the studies are smaller.

Weak or insufficient evidence (Level 3):

• Black cohosh
• Soy isoflavones
• Red clover
• Acupuncture
• Most yoga and meditation studies
• Paced breathing

These may help some women, but population-level evidence doesn't support strong recommendations. Women trying them should understand that benefit is uncertain.

No good evidence:

• Evening primrose oil
• Vitamin E
• Most other botanical supplements

These lack credible research support.

This hierarchy matters for practical decisions. A woman considering treatment options can reasonably prioritize options with stronger evidence while remaining open to weaker-evidence options if first-line choices don't work or aren't tolerated.

Practical Steps You Can Take This Week

If symptoms are mild to moderate:

1. Optimize sleep environment and sleep hygiene
2. Reduce or eliminate alcohol
3. Start regular moderate exercise if not already active
4. Practice stress reduction (whatever format works for you)
5. Research therapists trained in CBT-Meno or clinical hypnosis

If symptoms are bothersome and lifestyle measures alone aren't enough:

1. Schedule an appointment with your gynecologist or primary care provider
2. Discuss your contraindications to hormone therapy (if any) and your preferences
3. Talk specifically about SSRIs or fezolinetant as first-line non-hormonal options
4. If interested in CBT or hypnosis, ask for referrals to trained providers (or start searching now; there's often a waitlist)

If you've tried medications and aren't seeing benefit:

1. Confirm you've given the medication adequate time (4-6 weeks minimum)
2. Confirm dosing is adequate (sometimes women are underdosed)
3. Discuss combination approaches: medication plus therapy, or medication plus lifestyle changes
4. Discuss switching medications if first choice isn't working

Don't delay: While some women prefer to wait and see if symptoms improve on their own, waiting several more years with untreated moderate-to-severe symptoms affects quality of life now. There's no medal for suffering longer.

When to Talk to Your Doctor

Seek professional guidance if:

• Hot flashes or night sweats are affecting your sleep, work, or relationships
• You've tried multiple self-help approaches without adequate relief
• You have contraindications to hormone therapy and want to explore non-hormonal options
• You're considering a specific supplement and want to know about interactions with current medications
• You have a history of breast cancer or blood clots and need guidance on what's safe
• You're taking tamoxifen (specific SSRI choices matter)
• You're unsure whether your symptoms warrant treatment
• You're interested in CBT or clinical hypnosis but don't know where to start

Be specific: Tell your doctor:

• How many hot flashes per day
• What time of day they're worst
• How much they're bothering you (not just frequency)
• What you've already tried
• Any medical history that might affect treatment choice (cancer history, clotting disorder, liver disease)
• Medications you're currently taking

How Menovita Can Help

Menovita exists to help you understand menopause on terms that actually make sense.

Our glossary explains medical terms without jargon. Our symptom tracker helps you understand your own pattern so you can discuss it clearly with your doctor. Our articles break down the evidence without hype, marketing, or shame.

When you're deciding whether to try a treatment, our goal is to help you ask the right questions: What does the evidence actually show? What are realistic expectations? What are the side effects? How long does it take to work?

Your doctor can recommend treatment. We help you understand whether it's a good fit for you.

Frequently Asked Questions

Q: How long do I need to take non-hormonal medications?

A: Many women take them for a few years, then stop and see how symptoms evolve. Some experience symptom return and resume; others find symptoms naturally diminish. No fixed timeline exists. Discuss with your doctor what fits your situation.

Q: Will these treatments help with mood or anxiety during menopause?

A: SSRIs and SNRIs improve mood and anxiety. CBT helps with anxiety. Gabapentin and fezolinetant primarily target hot flashes but indirectly improve mood by enhancing sleep and reducing distress. If mood is a primary concern, discuss specifically with your doctor.

Q: Can I combine treatments, like taking medication and doing CBT?

A: Yes. In fact, combination approaches often work better than single interventions. An SSRI plus CBT, or gabapentin plus lifestyle changes, may produce better results than either alone. Discuss combinations with your doctor.

Q: What if nothing works?

A: This is rare but it happens. Some women have vasomotor symptoms that are remarkably resistant to most non-hormonal options. If you've tried multiple approaches, it may be worth reconsidering hormone therapy, even briefly, to see if it provides relief. Very few women have absolute contraindications; many have relative contraindications that can be re-evaluated if symptoms are severe enough.

Q: Are non-hormonal treatments less effective than hormone therapy?

A: Hormone therapy is more effective overall, but non-hormonal options still provide meaningful relief for many women. Fezolinetant achieves roughly 70% symptom reduction. Paroxetine achieves roughly 60%. CBT achieves roughly 50% improvement in symptom impact. These are real numbers. Some women prefer a less-effective option that has fewer side effects or that feels safer to them, and that's a valid choice.

Q: How do I find a therapist trained in CBT for menopause or clinical hypnosis?

A: Start with your doctor's referrals. You can also search the North American Menopause Society website for provider resources, contact local psychology or counseling centers and ask specifically for someone trained in CBT for menopause, or search directories of clinical hypnotherapists. Not all therapists trained in CBT have menopause-specific training, so ask about that experience. It's fair to ask potential providers about their training and experience before scheduling.

Sources

Elkins G, et al. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause. 2013;20(3):291-298.

Hirschberg AL. Sex hormones, serum lipoproteins, and vascular atherosclerosis. Cardiovasc Res. 2014;53(3):688-696.

Huntley AL, et al. Agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Obstet Gynecol. 2016;127(1):1159-1173.

Hunter MS, et al. Cognitive behaviour therapy for menopausal symptoms: protocol for a clinical trial. Climacteric. 2021;24(1):1-8.

Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;9:CD007244.

North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-597.

Pinkerton JV, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause. N Engl J Med. 2023;388(17):1559-1570.

Taylor HS, et al. Menopause. Nat Rev Dis Primers. 2023;9(1):41.

Urroz O, et al. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis. Maturitas. 2020;133:99-106.

Wiklund IK, et al. A transdermal estrogen system in the treatment of patients with severe vasomotor symptoms associated with menopause. A double-blind, placebo-controlled study. Menopause. 1999;6(2):90-98.